Abstract
We had earlier reported no difference in overall survival (OS) at a median follow up of 26 months of the first RCT comparing loco-regional treatment (LRT) vs not (no LRT) for the primary tumour in women with de novo metastatic breast cancer. We also noted then, a significant improvement in loco-regional progression free survival (PFS) and a significant detriment in distant PFS in LRT arm which reproduced findings of earlier animal experiments.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
